Pyramid Schemes and Pipeline Dreams: Adapting to a Tiered Regulatory System for New Drugs
This article was originally published in RPM Report
Executive Summary
FDA's new drug safety authorities suggest that the focus of drug development and lifecycle management strategies need to change. It is no longer a question of what it takes to get approval from FDA, but rather what kind of approval you can get.
You may also be interested in...
Regulatory Alchemy: The Transformative Power of the Opioid REMS
The three-year long process towards a class-wide Risk Evaluation & Mitigation Strategy has been anything but straightforward. Still, the final twist may be the most surprising: FDA is now espousing the most industry-friendly approach on the table. The details of the opioid REMS will take months to work out and years to judge, but understanding the choices made in crafting this policy are a critical starting point.
The Impact of FDAAA On Drug Approvals: Setting the Baseline
An analysis of the first six months of the new era in drug regulation shows that FDA is enthusiastically and creatively applying its new drug safety tools. Biopharma companies will be watching carefully to see how the metrics of the FDAAA era move over time.
The Impact of FDAAA On Drug Approvals: Setting the Baseline
An analysis of the first six months of the new era in drug regulation shows that FDA is enthusiastically and creatively applying its new drug safety tools. Biopharma companies will be watching carefully to see how the metrics of the FDAAA era move over time.